G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsGlobeNewsWire • 03/01/23
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 02/28/23
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023GlobeNewsWire • 02/22/23
G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/15/23
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)GlobeNewsWire • 02/13/23
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology ConferenceGlobeNewsWire • 01/11/23
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of TrilaciclibGlobeNewsWire • 01/09/23
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023GlobeNewsWire • 01/04/23
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor MicroenvironmentGlobeNewsWire • 12/07/22
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/23/22
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 11/02/22
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)GlobeNewsWire • 11/02/22
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 10/28/22
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung CancerGlobeNewsWire • 10/26/22